Verition Fund Management LLC Has $1.53 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Verition Fund Management LLC lowered its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 45.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,341 shares of the company's stock after selling 65,225 shares during the quarter. Verition Fund Management LLC owned approximately 0.09% of Syndax Pharmaceuticals worth $1,527,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in shares of Syndax Pharmaceuticals by 375.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,099 shares of the company's stock worth $406,000 after purchasing an additional 16,663 shares during the last quarter. Propel Bio Management LLC increased its position in Syndax Pharmaceuticals by 60.1% during the third quarter. Propel Bio Management LLC now owns 133,259 shares of the company's stock worth $2,565,000 after buying an additional 50,000 shares during the last quarter. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals during the third quarter valued at about $49,000. FMR LLC lifted its position in shares of Syndax Pharmaceuticals by 33.6% in the third quarter. FMR LLC now owns 49,248 shares of the company's stock worth $948,000 after buying an additional 12,377 shares during the last quarter. Finally, Algert Global LLC boosted its stake in shares of Syndax Pharmaceuticals by 9.9% during the 3rd quarter. Algert Global LLC now owns 474,998 shares of the company's stock worth $9,144,000 after acquiring an additional 42,870 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have commented on SNDX shares. Citigroup increased their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, November 19th. Bank of America lifted their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, August 15th. The Goldman Sachs Group upped their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a report on Thursday, November 7th. StockNews.com lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. Finally, Barclays increased their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.64.

Syndax Pharmaceuticals Trading Up 1.3 %

SNDX stock traded up $0.21 during midday trading on Friday, hitting $17.01. The stock had a trading volume of 1,477,544 shares, compared to its average volume of 2,235,721. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86. The stock has a 50-day simple moving average of $18.29 and a 200 day simple moving average of $19.66. Syndax Pharmaceuticals, Inc. has a 52 week low of $15.00 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the firm earned ($0.73) EPS. On average, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).